Edition:
India

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

13.60USD
1:30am IST
Change (% chg)

$-0.30 (-2.16%)
Prev Close
$13.90
Open
$13.85
Day's High
$13.85
Day's Low
$13.30
Volume
38,339
Avg. Vol
38,239
52-wk High
$18.00
52-wk Low
$6.85

Latest Key Developments (Source: Significant Developments)

Eiger Biopharmaceuticals Q4 Loss Per Share $1.11
Monday, 12 Mar 2018 

March 12 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.11.Q4 EARNINGS PER SHARE VIEW $-1.02 -- THOMSON REUTERS I/B/E/S.‍CASH RUNWAY EXTENDS THROUGH MID-2019​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article

EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Eiger Biopharmaceuticals Inc :EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.8 MILLION SHARES AT $10.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS & COMMISSIONS​.  Full Article

Eiger BioPharmaceuticals announces proposed public offering of common stock
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Eiger BioPharmaceuticals Inc :Eiger BioPharmaceuticals announces proposed public offering of common stock.Eiger BioPharmaceuticals - ‍intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates​.  Full Article

Eiger Biopharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 

Eiger Biopharmaceuticals Inc : Eiger Biopharmaceuticals announces pricing of public offering of common stock .Says public offering of 1.25 million common shares priced at $16.00per share.  Full Article

Eiger biopharmaceuticals announces proposed public offering of common stock
Thursday, 18 Aug 2016 

Eiger Biopharmaceuticals Inc : Announces proposed public offering of common stock .Eiger Biopharmaceuticals says intends to use net proceeds of offering to fund clinical development of its portfolio of four product candidates.  Full Article

Eiger Biopharmaceuticals Q2 loss per share $1.87
Thursday, 11 Aug 2016 

Eiger Biopharmaceuticals Inc : Q2 loss per share $1.87 . Eiger Biopharmaceuticals reports second quarter 2016 financial results .Q2 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.  Full Article